Aerie Pharma

AERI NASDAQ
23.12
-0.50
-2.12%
After Hours: 23.12 0 0.00% 17:04 07/19 EDT
Open
23.62
Prev Close
23.62
High
23.78
Low
22.45
Volume
1.05M
Avg Vol (3M)
650.68K
52 Week High
74.00
52 Week Low
22.45
% Turnover
2.28%
Market Cap
1.06B
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Aerie Pharma AERI stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company's product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan). The Company's product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Its Rhopressa is a once-daily eye drop. Rhopressa inhibits Rho kinase (ROCK), and the norepinephrine transporter (NET), which are both biochemical targets for lowering IOP. Its Roclatan is a once-daily, fixed-dose combination of Rhopressa and latanoprost, which is a prescribed drug for the treatment of patients with open-angle glaucoma. The Company is engaged in conducting Phase III clinical trial for Roclatan.
MORE >

Recently

Name
Price
%Change